Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3QFCV)

Drug Name
5-(4-Phenylbutoxy)psoralen Drug Info
Synonyms
4-(4-Phenylbutoxy)furo[3,2-g]chromen-7-one; Psora-4; Psora 4; 724709-68-6; 4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one; CHEMBL1256851; 4-(4-Phenylbutoxy)-7H-furo[3,2-g]chromen-7-one; 4-(4-Phenylbutoxy)-7H-furo[3,2-g][1]benzopyran-7-one; NCGC00015863-01; Lopac-P-9872; SCHEMBL2801777; GTPL9583; AC1O7G66; CTK8F0317; DTXSID10424970; MolPort-023-277-165; HMS3260K16; ZINC7997390; Psora-4, > Tox21_500137; BDBM50331458; AKOS024458119; LP00137; CCG-204232; NCGC00015863-02; NCGC00015863-03; NCGC00093627-02; NCGC00260822-01; NCGC00093627-01
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6603977
CAS Number
CAS 724709-68-6
TTD Drug ID
DM3QFCV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Voltage-gated potassium channel Kv1.3 (KCNA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Debio-0824 DMV401D Psoriasis vulgaris EA90 Phase 1b/2a [2]
Dalazatide DMJ1NG4 Inclusion body myositis 4A41.2 Phase 1b/2a [3]
UK-78282 DMKBILF Inflammation 1A00-CA43.1 Terminated [4]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [5]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [6]
2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide DM31E6J Discovery agent N.A. Investigative [7]
correolide DMACH7K Discovery agent N.A. Investigative [8]
Correloid DM5ISQK Discovery agent N.A. Investigative [9]
CP-339818 DMTJOWH Discovery agent N.A. Investigative [4]
[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine DMH3BG5 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv1.3 (KCNA3) TTY3UE6 KCNA3_HUMAN Inhibitor [1]

References

1 Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
2 Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
5 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
6 Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
7 Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
8 Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
9 Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
10 Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.